CD95-mediated tumor recognition by CD4+ effector cells in a murine mammary model

Journal of Immunotherapy

Volumn 23, Issue 2, 2000, Pages 225-234

  Aruga, Etsuko ^a   Tanigawa, Keishi ^c   Aruga, Atsushi ^a,b   Arai, Hiroshi ^d   Smith II, John W ^e   Nickoloff, Brian J ^f   Nabel, Gary J ^c   Chang, Alfred E ^c,g  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c UNIVERSITY OF MICHIGAN   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

^f LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^g NONE   (United States)

Author keywords

Adoptive immunotherapy; Breast neoplasm; Fas; FasL; T cells

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; FAS ANTIGEN; FAS LIGAND; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN RECOGNITION; ARTICLE; BREAST TUMOR; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; DENDRITIC CELL; EFFECTOR CELL; FEMALE; LUNG METASTASIS; LYMPH NODE CELL; LYMPHOCYTE DEPLETION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TUMOR REGRESSION;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, CD95; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; FAS LIGAND PROTEIN; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; LYMPH NODES; MAMMARY NEOPLASMS, EXPERIMENTAL; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION;

EID: 85026147085     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200003000-00007     Document Type: Article

References (29)

1. Barth RJ Jr, Mulé JJ, Spiess PJ, Rosenberg SA. Interferon-γ and tumor necrosis factor have a role in tumor regression mediated by murine CD8+ tumor-infiltrating lymphocytes. J Exp Med 1991; 173:647-58.
2. Aruga A, Aruga E, Tanigawa K, et al. Type 1 versus type 2 cytokine release by Vβ T cell subpopulations determines in vivo antitumor reactivity. J Immunol 1997;159:664-73.
3. Aruga A, Aruga E, Cameron MJ, Chang AE. Different cytokine profiles released by CD4+ and CD8+ tumor-draining lymph node cells involved in mediating tumor regression. Leukocyte Biol 1997; 61:507-16.
4. Nagoshi M, Goedegeebuure PS, Burger UL, et al. Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-γ and granulocyte/ macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes. J Immunol 1998;160:334-44.
5. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90: 3539-43.
6. Area MJ, Krauss JC, Aruga A, et al. Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor. Cancer Gene Therapy 1996;3:39-47.
7. Area MJ, Krauss JC, Aruga A, Cameron MJ, Chang AE: Concurrent induction of CD4+ and CD8+ T cells during tumor growth with antitumor reactivity in adoptive immunotherapy. J Immunother 1997;20:138-45.
8. Aruga E, Aruga A, Area MJ, et al. Immune responsiveness to a murine mammary carcinoma modified to express B7-1, interleukin-12, or GM-CSF. Cancer Gene Therapy 1997;4:157-66.
9. Margaretten NC, Witschi H. Effects of hyperoxia on growth characteristics of metastatic murine tumors in the lung. Cancer Res 1988;48:2779-83.
10. Yoshizawa H, Chang AE, Shu S. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J Immunol 1991;147:729-37.
11. Wexler H. Accurate identification of experimental pulmonary metastases. J Natl Cancer Inst 1966;36:641-5.
12. Arai H, Chan SY, Bishop DK, Nabel GJ. Inhibition of the alloantibody response by CD95 ligand. Nat Med 1997;3:843-8.
13. Nestle FO, Burg G, Fah J, Wrone-Smith T, Nickoloff BJ. Human sunlight-induced basal cell carcinoma are deficient in T cell co-stimulating molecules and are impaired as antigen-presenting cells. Am J Pathol 1998;150:641-52.
14. Metlay JP, Witmer-Pack MD, Agger R, et al. The distinct leukocyte integrins of mouse spleen dendritic cells as identified with new hamster monoclonal antibodies. J Exp Med 1990;171:1753-71.
15. Berke G. The CTL's kiss of death. Cell 1995;81:9-12.
16. Rouvier E, Luciani M, Golstein P. Fas involvement in Ca2+-independent T cell-mediated cytotoxicity. J Exp Med 1993;177: 195-200.
17. Hanabuchi S, Koyanagi M, Kawasaki A, et al. Fas and its ligand in a general mechanism of T-cell-mediated cytotoxicity. Proc Natl Acad Sci USA 1994;91:4930-4.
18. Walsh CM, Glass AA, Chiu V, Clark WR. The role of the fas lytic pathway in a perform-less CTL hybridoma. J Immunol 1994;153: 2506-14.
19. Lavy R, Mika YH, Rosen D, Berke G, Binah O. Lytic reaction of in vivo primed peritoneal exudate CTL. J Immunol 1995;154: 5039-48.
20. Ju S, Cui H, Panka DJ, Ettinger R, Marshak-Rothstein A. Participation of target fas protein in apoptosis pathway induced by CD4+ Th1 and CD8+ cytotoxic T cells. Proc Natl Acad Sci USA 1994; 91:4185-9.
21. Williams NS, Engelhard VH. Identification of a population of CD4+ CTL that utilizes a perforin-rather than a fas ligand-dependent cytotoxic mechanism. J Immunol 1996;156:153-9.
22. Vergelli M, Hemmer B, Muraro PA, et al. Human autoreactive CD4+ T cell clones use perform-or fas/fas ligand-mediated pathways for target cell lysis. J Immunol 1997;158:2756-61.
23. Hahne M, Rimoldi D, Schroter M, et al. Melanoma cell expression of fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996;274:1363-6.
24. Strand S, Hofmann WJ, Hug H, et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion. Nat Med 1996;2:1361-6.
25. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing fas ligand. J Exp Med 1996;184:1075-82.
26. Suda T, Okazaki T, Naito Y, et al. Expression of the fas ligand in cells of T cell lineage. J Immunol 1995;154:3806-13.
27. Tuttle TM, McCrady CW, Inge TH, Salour IM, Bear HD. Gamma-interferon plays a key role in T-cell-induced tumor regression. Cancer Res 1993;53:833.
28. Goedegebuure PS, Zuber M, Leonard VD, et al. Reactivation of murine tumour-infiltrating lymphocytes with solid-phase anti-CD3 antibody: in vitro cytokine production is associated with in vivo efficacy. Surg Oncol 1994;3:79.
29. Arai H, Gordon D, Nabel EG, Nabel GJ. Gene transfer of fas ligand induces tumor regression in vivo. Proc Natl Acad Sci U S A 1997;94:13862-7.